Abstract
Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued.
Original language | English (US) |
---|---|
Pages (from-to) | 212-215 |
Number of pages | 4 |
Journal | Pediatric Blood and Cancer |
Volume | 49 |
Issue number | 2 |
DOIs | |
State | Published - Aug 2007 |
Keywords
- Daclizumab
- Graft-versus-host disease
- Immunosuppression
- Infliximab
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology